Debbie Rigby takes a look at the latest in research news
Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative efficacy of tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate for the treatment of rheumatoid arthritis in patients with a previous inadequate response to methotrexate. Tofacitinib and methotrexate combination therapy was non-inferior to adalimumab and methotrexate combination therapy in the treatment of rheumatoid arthritis in patients with an inadequate response to methotrexate.
Lancet 2017; online.
The results from the phase 3 randomised FREEDOM trial and open-label extension show low rates of adverse events, low fracture incidence compared with that observed during the original trial, and continued increases in BMD without plateau with up to 10 years treatment with denosumab.
Lancet Diabetes Endocrinol. 2017.
A longitudinal observational cohort study of United States veterans suggests an excess risk of death among PPI users; risk is also increased among those without gastrointestinal conditions and with prolonged duration of use. Over a median follow-up of 5.71 years, PPI use was associated with a 25% increased risk of death compared with H2 blockers use.
BMJ Open 2017;7:e015735.
An Australian RCT has demonstrated that oral azithromycin 500mg three times a week for 48 weeks reduces asthma exacerbations and improves quality of life in adults with uncontrolled persistent asthma currently using optimal ICA/LABA therapy. Diarrhoea was more common in azithromycin-treated patients. The authors conclude that azithromycin might be a useful add-on therapy in patients with uncontrolled persistent asthma.